UK 'needs more transparency on pharma-doctor payments'
The UK's system of disclosing payments from pharma to healthcare professionals has gaps that hide potential conflicts of interest, claims study.
Verdiva Bio raises $411m for obesity pipeline
A new obesity startup – Verdiva Bio – has just decloaked with a whopping $411m to advance a once-weekly oral GLP-1 agonist.
AMD shadows NVIDIA with a move into AI drug discovery
Chipmaker AMD has taken a 20% stake in Absci, a specialist in the use of artificial intelligence in for biologic drug discovery.
Grifols files drug for rare bleeding disorder in the US
Grifols has filed for FDA approval of its new drug for bleeding disorder acquired fibrinogen deficiency (AFD), aiming for a first-in-class US launch.
Is GSK prepping a $1bn takeover bid for IDRx?
GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
hubXchange returns with its latest series of roundtables!
hubXchange invites you to participate in its highly-anticipated San Diego Series 2025, a series of focused, high-level roundtable events designed to address key challenges and innovations across th
Advance Best-In-Class Treatment Across CNS, Emergency Use Tr...
With nasal delivery systems offering faster absorption and non-invasive administration, they are becoming a cornerstone of modern therapeutics.
7th Treg-Directed Therapies Summit
Unravelling Treg Biology, Pioneering Best-in-Class Approaches & Demonstrating Clinical Efficacy to Advance Validated Therapeutic Options in Autoimmunity, Inflammation & Beyond
Welcome to the Bacteriophage Therapy Summit!
Combating Antibiotic Resistance with Effective & Sustainable Phage-Based Therapies
Biotech Showcase marking 17 years of innovation and opportun...
Biotech Showcase is a cornerstone of the life science industry, with a 17-year history of connecting private and micro- to mid-cap biotech companies with top-tier investors and biopharmaceu